Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line t... by S De Groot, H M Blommestein, W K Redekop, S Sleijfer, L A L M Kiemeney, E Oosterwijk, C A Uyl-de Groot

Get full text

P53 REAL-WORLD TREATMENT SEQUENCES AND COSTS OF 96 PATIENTS WITH MULTIPLE MYELOMA FROM DIAGNOSIS TO DEATH by M.R. Seefat, D.G.J. Cucchi, K. Groen, M.L. Donker, K.G. van der Hem, M. Westerman, A.M. Gerrits, A. Beeker, N. van de Donk, H.M. Blommestein, S. Zweegman

Get full text

P12 HEALTH-RELATED QUALITY OF LIFE IN FRAIL AND INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DOSE-ADJUSTED MELPHALAN-PREDNISONE-BORTEZOMIB (MPV) by M.R. Seefat, C.A.M. Stege, G.J. Timmers, M.D. Levin, M. Hoogendoorn, P.F. Ypma, I.S. Nijhof, G.A. Velders, L. Strobbe, N. Durdu-Rayman, M. Westerman, M.A. Davidis-van Schoonhoven, R.J.W. van Kampen, A. Beeker, A. Koster, A.C. Dijk, N.W.C.J. van de Donk, E. van der Spek, M.B.L. Leys, M.H. Silbermann, K. Groen, N.C.H.P. van der Burg-de Graauw, H.A.M. Sinnige, K.G. van der Hem, T.H. Levenga, Y.M. Bilgin, P. Sonneveld, S.K. Klein, K. Nasserinejad, H.M. Blommestein, D.G.J. Cucchi, B.I. Lissenberg-Witte, S. Zweegman

Get full text